source
- Regulatory update: Hepatitis B hold lifted for Arbutus drug and Ultomiris receives accelerated approvalA regulatory update notes that the FDA has removed the clinical hold on Arbutus Biopharma's hepatitis B candidate, clearing the path for the company to resume development after a prolonged review.…
- AbbVie reports Phase 3 success for lutikizumab in painful skin disease, eyes FDA filing next yearAbbVie announced positive Phase 3 trial results for its experimental IL-1α and IL-1β inhibitor lutikizumab, which is being developed to treat a debilitating skin condition. The study reported impr…